Literature DB >> 16158061

IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells.

Nicolle M Linnerth1, Mitch Baldwin, Craig Campbell, Melissa Brown, Heather McGowan, Roger A Moorehead.   

Abstract

We have previously shown that lung tumors arising in MMTV-IGF-II transgenic mice displayed elevated levels of phosphorylated cAMP response element binding protein (CREB). To investigate the role that insulin-like growth factor II (IGF-II) and CREB play in human lung tumorigenesis, A549 and NCI-H358 cells were examined. In these cell lines, IGF-II administration enhances human tumor cell survival and CREB phosphorylation. Further, the effects of IGF-II on cell survival and CREB phosphorylation appeared to be mediated, at least in part, by activation of the Erk pathways, as inhibition of these signaling pathways reduced tumor cell survival and CREB phosphorylation. Specifically, Erk5 appeared as the predominant mediator of CREB phosporylation. To further verify the importance of CREB in human lung tumorigenesis, A549 and NCI-H358 cells were stably transfected with a vector containing a dominant negative CREB construct (KCREB). KCREB transfection significantly inhibited the soft agar growth of both human tumor cell lines. In contrast, overexpression of wild-type CREB in the normal human bronchial epithelial cell line, HBE135, enhanced soft agar growth. Therefore, our results indicate that CREB and its associated proteins play a significant role in lung adenocarcinoma and IGF-II induces CREB phosphorylation, at least in part, via the Erk5 signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16158061     DOI: 10.1038/sj.onc.1208882

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

1.  Targeting CREB for cancer therapy: friend or foe.

Authors:  Xiangshu Xiao; Bingbing X Li; Bryan Mitton; Alan Ikeda; Kathleen M Sakamoto
Journal:  Curr Cancer Drug Targets       Date:  2010-06       Impact factor: 3.428

Review 2.  Inhibition of Ras-mediated signaling pathways in CML stem cells.

Authors:  Jessika Bertacchini; Neda Ketabchi; Laura Mediani; Silvano Capitani; Sandra Marmiroli; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-10-12       Impact factor: 6.730

3.  Gene networks in basal cell carcinoma of the eyelid, analyzed using gene expression profiling.

Authors:  Tatsuya Yunoki; Yoshiaki Tabuchi; Tetsushi Hirano; Shigeharu Miwa; Johji Imura; Atsushi Hayashi
Journal:  Oncol Lett       Date:  2018-09-21       Impact factor: 2.967

4.  Type I insulin-like growth factor receptor induces pulmonary tumorigenesis.

Authors:  Nicolle M Linnerth; Megan D Siwicky; Craig I Campbell; Katrina L M Watson; James J Petrik; Jeffrey A Whitsett; Roger A Moorehead
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

5.  Nuclear localization and functional characteristics of voltage-gated potassium channel Kv1.3.

Authors:  Soo Hwa Jang; Jun Kyu Byun; Won-Il Jeon; Seon Young Choi; Jin Park; Bo Hyung Lee; Ji Eun Yang; Jin Bong Park; Scott M O'Grady; Dae-Yong Kim; Pan Dong Ryu; Sang-Woo Joo; So Yeong Lee
Journal:  J Biol Chem       Date:  2015-03-31       Impact factor: 5.157

6.  β-arrestin-2 regulation of the cAMP response element binding protein.

Authors:  Mary E Manson; Deborah A Corey; Sharon M Rymut; Thomas J Kelley
Journal:  Biochemistry       Date:  2011-06-15       Impact factor: 3.162

7.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

8.  Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein.

Authors:  Sita Aggarwal; Seung-Wook Kim; Seung-Hee Ryu; Wen-Cheng Chung; Ja Seok Koo
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

9.  Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer.

Authors:  Hye-Sook Seo; Diane D Liu; B Nebiyou Bekele; Mi-Kyoung Kim; Katherine Pisters; Scott M Lippman; Ignacio I Wistuba; Ja Seok Koo
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

10.  ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.

Authors:  Craig I Campbell; James J Petrik; Roger A Moorehead
Journal:  Mol Cancer       Date:  2010-09-08       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.